A Phase 3 Randomized, Open-Label Study comparing Pexa-Vec (Vaccinia Gm-CSF/Thymidine Kinase- Deactivated Virus) followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) without Prior Systemic Therapy
|Effective start/end date||1/1/16 → 9/30/20|
- SILLAJEN USA, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.